vogoat, It cannot have been out from BEFORE the SUNRISE stop. The document dates from APRIL 2016. PPHM and NCCN are both mentioned as the collaborating partners and this document would NEVER have gone public or inside the NCCN Network WITHOUT PPHM's approval.
In APRIL 2016 PPHM had already stopped SUNRISE so it is IMPOSSIBLE that this document would have been released with any content from BEFORE SUNRISE was stopped. PPHM had 2 months to update it and their PR's (last Update PR) and Q/CC have constantly hammered on the 2 to 5 clinical trials from NCCN to be coming. Furthermore it is on their web-site now.
Now we know that:
- Yesterday was the date-line for proposals
- That Chemo Combo's may not be proposed (only I-O)
- That PIII are excluded
- That the Durvalumab (AstraZeneca) and now also a KeyTruda (Merck) clinical trial with Bavituximab are coming and have been decided on.
- That NON of the trials are pre-clinical (that work has been done by UTSW and the combined Thorpe/Brekken labs and possibly REDONE at some extend by Memorial Sloan Kettering.
It means that 3 of the 4 main Immuno-Oncology players (BMY, MERCK, ROCHE and AstraZeneca) had/will have an I-O drug combined with Bavituximab. Yervoy, KeyTruda and Durvalumab, a CTLA-4, PD-1, PD-L1. And KeyTruda+Bavi goes after the new Opdivo SOC in Melanoma. In APRIL 2016 it was WRITTEN AS FACT that that trial would take place because it was at that time excluded EXPLICITLY and BY NAME as a possible combination for NCCN member proposals.
Market Data 
Markets 
AI
